Aims to redefine the standard for assessment of suspected UTI specimens.
Rapid screening tool for specimens submitted for suspicion of bacteremia.
An automated, rapid minimum inhibitory concentration assay for positive blood culture samples that works directly out of positive bottles.
Aperture Bio's RAPID-B platform technology is the first commercial quantitative microbiological platform to be applied to infectious disease testing. Based on nextgen flow cytometric principles coupled to high-throughput automation to meet the demands of the 21st century clinical microbiology laboratory, the platform aims to redefine the approach to suspected bacterial infections.
Fluidics and laser optimization coupled to Aperture's proprietary sample chemistry allow for robust and accurate gating protocols that enable highly accurate live bacterial cell enumeration in minutes...This is the foundation of Aperture Bio's clinical assays.
The application of Aperture's technology to samples suspected of containing pathogenic bacteria has the ability to transform the way these patients are diagnosed and treated. For example, the rapid nature and high accuracy of our UTI assay when applied to uncomplicated, outpatient UTI patients can improve outcomes by providing treating physicians fast confirmation of UTI microbiology AND direct appropriate therapy for these patients. Currently, no technology exists to provide this information...information that is critical in the context of dramatically rising antibiotic resistance rates.
The application of the Aperture Bio technology to suspected bloodstream infections also has the potential to dramatically change the way these patients are approached.
Early data suggests the empiriSTAT Blood assay can detect the presence of bacteria in blood samples in half the time of current carbon dioxide-sensing platforms. Coupled with Aperture's Antibiotic Predictive Profile the empiriSTAT Blood assay aims to provide important actionable data to treating physicians to reduce mortality and improve outcomes by getting efficacious antimicrobials on board sooner.
Aperture Bio's empiriSTAT UTI test aims to redefine the standard for assessment of suspected UTI specimens. With screening results in under 10 minutes initial bacterial counts and leukocyte counts are provided to the user. System robotics prepares samples with bacteria >100,000 per milliliter by automatically diluting the sample in cation-adjusted Mueller-Hinton II media and depositing the sample in appropriate wells containing standard empiric therapies used for UTI (Trimethoprim-Sulfamethoxazole, Nitrofurantoin, Ciprofloxacin, Cefazolin, Amoxicillin-Clavulanate). After a short-course incubation of 2.5 hours proprietary algorithms confirm the presence of a uropathogen and perform a phenotypic assessment of antibiotic effect on bacterial growth. Internal data suggests sensitivity >97% and specificity >88% compared to traditional urine cultures, including those containing high levels of urogenital floral contaminants.
With performance as accurate and results as rapid as the empiriSTAT UTI test Aperture Bio sees the possibility of market expansion into the outpatient UTI sector, including skilled nursing home facilities where UTI is a major driver of hospital admission. Currently many guidelines don't recommend culture of suspected UTI patients due to the lengthy culture times and suggest empiric therapy based on signs and symptoms alone. Unfortunately, the dramatic rise in resistance rates to standard therapies is making this approach unsustainable. With the empiriSTAT UTI test as an option Aperture Bio aims to change this alarming trend.
Aperture Bio is developing a rapid screening tool for specimens submitted for suspicion of bacteremia. By applying their proprietary chemistry and algorithms Aperture has been able to determine positive blood cultures in approximately half the time as traditional methods. With the addition of Aperture's Antibiotic Predictive Profile treating physicians can narrow their therapeutic approach prior to the second dose of empiric therapy.
Aperture Bio is developing an automated, rapid minimum inhibitory concentration assay for positive blood culture samples that works directly out of positive bottles. With both a Gram positive and Gram negative panel the m.i.c.STAT assay evaluates the phenotypic effect of standard antibiotics at 5 hours with a confirmatory industry-standard 18 hour evaluation for determination of any delayed-resistance phenotypes. This high-throughput application will allow for parallel assessment of samples at a fraction of the cost of competitors.